Korean J Urol Oncol.  2016 Aug;14(2):69-75. 10.22465/kjuo.2016.14.2.69.

Is the Expression of p53, c-erb-B2 and Ki-67 Influence the Prognosis of the Non-muscle Invasive Urothelial Bladder Cancer?

• Kang SH
• Jung HJ
• Yang EK
• Park JS
• Oh HK
• Kim DY

• KMID: 2361566
• DOI: http://doi.org/10.22465/kjuo.2016.14.2.69

Abstract

PURPOSE
The immunohistochemial markers can be used to predict prognosis more accurately for several cancers. In non-muscle invasive urothelial carcinoma, p53, c-erb-B2 and Ki-67 are applicable. We investigated a retrospective analysis of the relation between the markers and clinical prognostic factors of urothelial bladder cancer.
MATERIALS AND METHODS
Data from 268 non-muscle invasive urothelial bladder cancer (Ta, T1) patients from one single center were collected. Immunohistochemical evaluation was carried out on 268 (p53, c-erb-B2, Ki-67) cases. Clinical prognostic factors are as follows; number of tumor, tumor invasiveness, tumor grade and recurrence. The sum of all positivity of 3 markers was made as a new factor and evaluation of correlation between this factor and prognostic factors was also done. Statistical analysis was done by chi-squares test and Pearson's correlation test.
RESULTS
Through chi-square test, there were significant relations between all markers and tumor invasiveness (p<0.001), tumor grade (p<0.001). Number of tumor is significantly related with Ki-67 (p=0.043). Recurrence is related with c-erb-B2 (p=0.010) and Ki-67 (p=0.043). There was also significant correlations between the sum of the markers and prognostic factors-tumor invasiveness (p<0,001), tumor grade (p<0.001) and recurrence (p=0.007).
CONCLUSIONS
In this study, evaluated markers were closely related with clinical prognostic factors and may contribute to decision making on risk-assessment and management strategy for non-muscle invasive urothelial bladder cancer.

Keyword

Urinary bladder neoplasms; Immunohistochemistry; Risk assessment

MeSH Terms

Decision Making
Humans
Immunohistochemistry
Prognosis*
Recurrence
Retrospective Studies
Risk Assessment
Urinary Bladder Neoplasms*
Urinary Bladder*